UNIV. MILAN

UNIV. ABERDEEN

Institute of Medical Science, School of Medicine, Medical Science and Nutrition, UK

UNIV. ANTWERP

Laboratory of Physiopharmacology, Belgium

UNIV. BARCELONA

Department of Biochemistry and Molecular Biology, Spain

UNIV. LEIDEN

Department of Surgery and Einthoven Laboratory for Experimental Vascular Medicine, The Netherlands

TOGETHER

Marie Skłodowska-Curie ITN-European Joint Doctorate

RECENT EVENT

MOGLYNET WORKSHOP

"Generation of patient endothelial cell lines:

study of cellular metabolism and mitochondria”

IDIBAPS, Barcelona, Spain - January 14, 2019

Open event

For registration please contact Sabrina Pavan: secretary@moglynet.com

Marie Skłodowska-Curie ITN-European Joint Doctorate

MOGLYNET-PhD programme in drug discovery and development

The Horizon 2020 MSCA joint doctoral project MoGglyNet (“Modulation of glycolytic flux as a new approach for treatment of atherosclerosis and plaque stabilization: a multidisciplinary study”) is running by a Consortium of Universities in cooperation with Pharma Industries and Associations. The programme was established with the aim of providing 12 Early Stage Researchers with innovative PhD trainings in Drug Discovery and Development.

HOW IT WORKS

The MOGLYNET PhD programme aims to define a new joint PhD educational model in Drug Discovery and Development and to promote institutional cooperation and mobility.

An active contribution of Industry in training activities is an important feature of the programme. The research methodologies and approaches proposed by the MOGLYNET consortium are strongly multidisciplinary and will involve a number of different state-of-the-art technologies and methodologies. These includes computational chemistry, chemical synthesis, bioanalytics, biophysics, in vitro biological evaluations, in vivo studies, imaging, metabolomics, proteomics, and oxidative stress studies.

OUR PARTNERS

WE SEE THE FUTURE

MOGLYNET IN NUMBERS

0

UNIVERSITIES

0

INDUSTRIAL PARTNERS

0

EUROPEAN ASSOCIATIONS

0

PhD FELLOWSHIPS

WHAT WE THINK ABOUT MOGLYNET

Dr.ssa Anni Svala

The non-academic contribution provides the way forward to help academia in meeting the educational needs of pharmaceutical industry.

Prof.ssa Marina Carini

The exposure of recruited researchers to different environments is specifically designed to integrate and complement the sectorial knowledge of the fellow allowing the creation of a common knowledge and language for ESRs.

Dr. Stefano Bellosta

Synergy between all the participants is fundamental to reach the goals planned by MOGLYNET programme.

Prof. Matteo Zanda

MOGLYNET EJD stems from six Doctoral Courses/Schools at the five beneficiary institutions providing research and training in the field of drug discovery and health. A double degree in Drug Discovery and Development will be delivered by two Accademic beneficiaries.

Dr.ssa Mirela Delibegovic

The research methodologies and approaches proposed by the MOGLYNET consortium are strongly multidisciplinary (from molecular modelling to in vivo studies) and will involve a number of different state-of-the-art technologies and methodologies.

Prof. Guido De Meyer

We are a consortium of excellence in the atherosclerosis field. The research strategy proposed by MOGLYNET to takle atherosclerosis, which is a major unmet medical need, is higly original and innovative.

Prof. Paul Quax

Atherosclerotic cardiovascular disease is a disease of aging and is the major cause of death in the western world and for this reason there is a strong high need for additional pharmacological interventions.

Prof. Francesca Clerici

The European Commission has identified active and healthy aging as a major societal challenge common to all European countries, and an area which presents considerable potential for Europe to lead the world in providing innovative responses to this challenge.

Prof. Maria Luisa Gelmi

The transfer of “what” a researcher know in “how” to realize this in a complex system related to the drug is not trivial and requires a wide overall view of the problem. The mission of MOGLYNET is to define a joint doctorate educational training model where Academia and Industry Join their forces to reach this target.

We are the MOGLYNET-PhD programme in drug discovery and development.
The Horizon 2020 MSCA joint doctoral project MOGLYNET (“Modulation of glycolytic flux as a new approach for treatment of atherosclerosis and plaque stabilization: a multidisciplinary study”) is run by a Consortium of Universities in cooperation with Industries and Associations operating in the Pharma sector with the aim to offer an innovative PhD level training in Drug Discovery and Development to 12 Early Stage Researchers